Clinical trials: Androgens
Prostatic Cancer
Quinacrine Treatment in Patients With Androgen-Independent Prostate Cancer
The purpose of this study is to determine whether quinacrine is effective in the treatment of Androgen-Independent Prostate Cancer.
- Trial name
- NCT00417274
- Testing
- Quinacrine
- Volunteers
- 31 people
- Sponsor
- Cleveland BioLabs
Prostatic Neoplasms
A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer
The purpose of this study is to evaluate how well JNJ-101556143 plus Best Supportive Care (BSC) improves overall survival (the length of time a participant remains alive) compared with placebo plus BSC in participants with…
- Trial name
- NCT07906717
- Testing
- JNJ-101556143, Best Supportive Care
- Volunteers
- 400 people
- Sponsor
- Janssen Research & Development, LLC
Hypogonadism
A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel
The purpose of this study is to assess the change in 24-hour ambulatory blood pressure monitoring (ABPM) between baseline (Day 0) and Day 120 following 4 months of testosterone therapy with Natesto.
- Trial name
- NCT04976595
- Testing
- Natesto
- Where
- 30 sites in United States
- Volunteers
- 218 people
- Sponsor
- Acerus Pharmaceuticals Corporation
Prostate Neoplasms
An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
The purpose of this study is to assess the anti-tumor activities and safety of abiraterone acetate in participants with prostate cancer (a disease in which cells in the prostate gland [a gland in the male reproductive system…
- Trial name
- NCT00474383
- Testing
- Abiraterone acetate, Glucocorticoid
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 47 people
- Sponsor
- Cougar Biotechnology, Inc.
Prostate Cancer
An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer
This was an extension study for the study FE200486 CS12 (NCT00819156). Each participant was to be treated until he was discontinued or withdrawn from the study, or a marketing authorization for degarelix had been obtained.
- Trial name
- NCT00215683
- Testing
- Degarelix
- Where
- 34 sites in Belgium, Germany and 5 more
- Volunteers
- 137 people
- Sponsor
- Ferring Pharmaceuticals
Prostatic Neoplasms, Castration-Resistant
A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical…
- Trial name
- NCT07677254
- Where
- United States
- Volunteers
- 17,111 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis
This study is being conducted to evaluate the effect of an investigational drug on bone loss in men with prostate cancer who are receiving Androgen Deprivation Therapy (ADT).
- Trial name
- NCT00171639
- Testing
- zoledronic acid
- Where
- 7 sites in United States
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Castrate-resistant Prostate Cancer, Adenocarcinoma, Prostate
Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients
This is a multi-center, first-in-human, open-label, Phase 1/2A dose-escalation study in which eligible patients with metastatic castration-resistant prostate carcinoma (mCRPC) will receive oral doses of TRC253.
- Trial name
- NCT02987829
- Testing
- TRC253
- Where
- 5 sites in United States
- Volunteers
- 72 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Prostatic Neoplasms
Safety Study of TAK-700 in Subjects With Prostate Cancer.
The purpose of this study is to determine the safety and tolerability of TAK-700 in patients with asymptomatic metastatic, androgen independent prostate cancer.
- Trial name
- TAK-700 (NCT00569153)
- Testing
- TAK-700
- Where
- 19 sites in United States
- Volunteers
- 123 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
COVID-19, SARS-CoV2
Anti-Androgen Treatment for COVID-19
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
- Conditions
- COVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate Cancer
- Trial name
- NCT04446429
- Testing
- Proxalutamide, Standard of Care
- Where
- Brazil
- Volunteers
- 268 people
- Sponsor
- Applied Biology, Inc.
Prostate Cancer
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
The primary objectives of this study are: 1. To explore the antitumor activity of MEDI-522 in combination with docetaxel, prednisone, and zoledronic acid in patients with metastatic Androgen-Independent Prostate Cancer (AIPC)…
- Trial name
- NCT00072930
- Testing
- MEDI-522, Docetaxel + Prednisone* + Zoledronic Acid
- Where
- 57 sites in United States, Belgium and 5 more
- Volunteers
- 150 people
- Sponsor
- MedImmune LLC
Prostate Cancer
Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer
Docetaxel (Taxotere) is an approved chemotherapeutic drug for the treatment of androgen-independent prostate cancer. The aim of the study is to investigate whether addition of the investigational drug PI-88 will increase the…
- Trial name
- NCT00268593
- Testing
- PI-88, docetaxel, prednisone
- Where
- 8 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Progen Pharmaceuticals
Castration-Resistant Prostate Cancer (CRPC)
A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100
A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who have already undergone treatment with MDV3100 and showed benefit.
- Trial name
- NCT01534052
- Testing
- Enzalutamide
- Where
- 7 sites in United States, Moldova and 1 more
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Inc
Polycystic Ovary Syndrome
A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
An investigation of the safety and efficacy of tildacerfont in women with PCOS and elevated adrenal androgens
- Trial name
- NCT05370521
- Testing
- Tildacerfont
- Where
- 21 sites in United States
- Volunteers
- 27 people
- Sponsor
- Spruce Biosciences
Prostate Cancer
Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
This was an extension study for the study FE200486 CS14 (NCT00116779). Each participant was to be treated until he was discontinued or withdrawn from the study, or a marketing authorization for degarelix had been obtained.
- Trial name
- NCT00117286
- Testing
- Degarelix
- Where
- 22 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Open-Label, Randomised Parallel-Group Study
An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation Therapy.
- Trial name
- NCT00728533
- Testing
- Degarelix
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer
The purpose of the study was to contribute, along with other such dose-finding studies, to the identification of the most effective treatment regimen for a one month depot injection of degarelix in the treatment of prostate…
- Trial name
- NCT00116779
- Testing
- Degarelix
- Where
- 35 sites in United States, Canada
- Volunteers
- 127 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy
The study will have two treatment groups, evaluating two Degarelix doses. First dose is the initial dose followed by a maintenance dose given every three months.
- Trial name
- NCT00468286
- Testing
- Degarelix
- Where
- 29 sites in United States, Canada and 3 more
- Volunteers
- 133 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients
To investigate the long-term safety and tolerability of repeated doses of degarelix to prostate cancer patients
- Trial name
- NCT00245466
- Testing
- Degarelix
- Volunteers
- 88 people
- Sponsor
- Ferring Pharmaceuticals
Known Androgen Deficiency
Comparison of Salivary and Serum Free Testosterone in Normal and Hypogonadal Men
Low testosterone is a common male problem. The diagnosis of low testosterone often requires blood sampling and expensive testing. We want to know if measuring saliva testosterone can be used in place of blood sampling.
- Trial name
- NCT01909505
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Saliva Biomarkers, Inc.